Safety and tolerability of adjunct non-invasive vagus nerve stimulation in people with parkinson’s: a study protocol

Abstract

Background Parkinson’s disease (PD) is the fastest growing neurological condition worldwide. Recent theories suggest that symptoms of PD may arise due to spread of Lewy-body pathology where the process begins in the gut and propagate transynaptically via the vagus nerve to the central nervous system. In PD, gait impairments are common motor manifestations that are progressive and can appear early in the disease course. As therapies to mitigate gait impairments are limited, novel interventions targeting these and their consequences, i.e., reducing the risk of falls, are urgently needed. Non-invasive vagus nerve stimulation (nVNS) is a neuromodulation technique targeting the vagus nerve. We recently showed in a small pilot trial that a single dose of nVNS improved (decreased) discrete gait variability characteristics in those receiving active stimulation relative to those receiving sham stimulation. Further multi-dose, multi-session studies are needed to assess the safety and tolerability of the stimulation and if improvement in gait is sustained over time. Design This will be an investigator-initiated, single-site, proof-of-concept, double-blind sham-controlled randomised pilot trial in 40 people with PD. Participants will be randomly assigned on a 1:1 ratio to receive either active or sham transcutaneous cervical VNS. All participants will undergo comprehensive cognitive, autonomic and gait assessments during three sessions over 24 weeks, in addition to remote monitoring of ambulatory activity and falls, and exploratory analyses of cholinergic peripheral plasma markers. The primary outcome measure is the safety and tolerability of multi-dose nVNS in PD. Secondary outcomes include improvements in gait, cognition and autonomic function that will be summarised using descriptive statistics. Discussion This study will report on the proportion of eligible and enrolled patients, rates of eligibility and reasons for ineligibility. Adverse events will be recorded informing on the safety and device tolerability in PD. This study will additionally provide us with information for sample size calculations for future studies and evidence whether improvement in gait control is enhanced when nVNS is delivered repeatedly and sustained over time. Trial registration This trial is prospectively registered at www.isrctn.com/ISRCTN19394828. Registered August 23, 2021.

Neuromorphic electro-stimulation based on atomically thin semiconductor for damage-free inflammation inhibition

“…Electro-stimulation (ES) of peripheral nerves is emerging as an anti-inflammatory therapy that intervenes in inflammatory cell activity by modulating bioelectrical signals, neurotransmitters to bring about relief from inflammation 9 . Vagal nerve stimulation initially became a common option 10 – 12 , where afferent vagal fibers are stimulated to transmit signals and signals reach the target organ via efferent vagal nerve or sympathetic trunk to regulate inflammation 13 , 14 . Typical stimulation currents are 0.25−0.8 mA 15 , 16 , high currents may lead to tissue damage and complications.…”